SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS
The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatme...
Saved in:
| Main Authors | , , , , |
|---|---|
| Format | Patent |
| Language | English Korean |
| Published |
20.04.2011
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I). |
|---|---|
| AbstractList | The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I). |
| Author | TOMMASI RUBEN ALBERTO WEILER SVEN SHULTZ MICHAEL MCQUIRE LESLIE WIGHTON ROGEL OLIVIER |
| Author_xml | – fullname: MCQUIRE LESLIE WIGHTON – fullname: WEILER SVEN – fullname: ROGEL OLIVIER – fullname: TOMMASI RUBEN ALBERTO – fullname: SHULTZ MICHAEL |
| BookMark | eNrjYmDJy89L5WSwCXb1cXUO8QxzVfCIdAnyj3D09XRWcHT2dFFwcgx2dVHw9Q3QNTRScPSDMo0VPP08PJ08Q_yDgnkYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSbx3kJGBoaGBgYmBpaGhozFxqgBnTitS |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| ExternalDocumentID | KR20110040911A |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_KR20110040911A3 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 15:57:49 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English Korean |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_KR20110040911A3 |
| Notes | Application Number: KR20117003227 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110420&DB=EPODOC&CC=KR&NR=20110040911A |
| ParticipantIDs | epo_espacenet_KR20110040911A |
| PublicationCentury | 2000 |
| PublicationDate | 20110420 |
| PublicationDateYYYYMMDD | 2011-04-20 |
| PublicationDate_xml | – month: 04 year: 2011 text: 20110420 day: 20 |
| PublicationDecade | 2010 |
| PublicationYear | 2011 |
| RelatedCompanies | NOVARTIS AG |
| RelatedCompanies_xml | – name: NOVARTIS AG |
| Score | 2.7696903 |
| Snippet | The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110420&DB=EPODOC&locale=&CC=KR&NR=20110040911A |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8NADA9zivqmU_FjyoHSt2LXXu0KDmnvbrTOtqOrMp9Gr60gyjZcxX_frNt0T3sLFwi5kN9dSC4XgBtpm0WqybaqWXmmUoxo1VTTMnVe47L0XDesajZgEN55z_RxaA5r8Lnqhan-Cf2pPkdERGWI97I6r6f_SSxeva2c3cp3XJo8dJMOV_JVug99UFO42xH9iEdMYazTi5UwXvDQYRHbzhZsYyBtzfEgXtx5X8p0_VLpHsBOH-WNy0OofUwasMdWs9casBssS95ILtE3O4L7gXgSLPFfBPFeeRwNHbQhcZjPiesMBCdB0FdbOnHCJWkQP_R810-ieHAM112RME9FNUZ_ux714nWdjROojyfj4hSImdnS0HMqaWrTlqVJSe0sN9vSTAv7rZWeQXOTpPPN7AvYX6RNKQKoCfXy67u4xHu3lFeVuX4B2lN-0A |
| link.rule.ids | 230,309,783,888,25576,76876 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8NADA9zivNNp-LH1AOlb8WuvdoVHNJeb7RubUdXx3wavbaCKNtwFf99s27TPe0tXCDkQn53IblcAO6EqeeJIlqyYmSpTDGilRNFSeVFjctQM1UzytmAfvDgvtDnkT6qwOe6F6b8J_Sn_BwREZUi3ovyvJ79J7Gc8m3l_F6849L0qRO3HSlbp_vQBxXJsdu8HzohkxhrdyMpiJY8dFjEtrUDuxhkGws88KG96EuZbV4qnUPY66O8SXEElY9pHWpsPXutDvv-quSN5Ap982N4HPAeZ7E35MR9daJwZKENicU8h9jWgDvE9_tyUyVWsCI14gWuZ3txGA1O4LbDY-bKqMb4b9fjbrSps3YK1cl0kp8B0VNTaGpGBU1M2jQUIaiZZnpL6EluvjWTc2hsk3SxnX0DNTf2e-OeF3Qv4WCZQqUIpgZUi6_v_Arv4EJcl6b7BfjqgcM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=SELECTIVE+HYDROXAMIC+ACID+BASED+MMP-12+AND+MMP-13+INHIBITORS&rft.inventor=MCQUIRE+LESLIE+WIGHTON&rft.inventor=WEILER+SVEN&rft.inventor=ROGEL+OLIVIER&rft.inventor=TOMMASI+RUBEN+ALBERTO&rft.inventor=SHULTZ+MICHAEL&rft.date=2011-04-20&rft.externalDBID=A&rft.externalDocID=KR20110040911A |